Cargando…
Dysfunctional Sars-CoV-2-M protein-specific cytotoxic T lymphocytes in patients recovering from severe COVID-19
Although the importance of virus-specific cytotoxic T lymphocytes (CTL) in virus clearance is evident in COVID-19, the characteristics of virus-specific CTLs related to disease severity have not been fully explored. Here we show that the phenotype of virus-specific CTLs against immunoprevalent epito...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9758236/ https://www.ncbi.nlm.nih.gov/pubmed/36526616 http://dx.doi.org/10.1038/s41467-022-34655-1 |
_version_ | 1784851998966808576 |
---|---|
author | Ogura, Hideki Gohda, Jin Lu, Xiuyuan Yamamoto, Mizuki Takesue, Yoshio Son, Aoi Doi, Sadayuki Matsushita, Kazuyuki Isobe, Fumitaka Fukuda, Yoshihiro Huang, Tai-Ping Ueno, Takamasa Mambo, Naomi Murakami, Hiromoto Kawaguchi, Yasushi Inoue, Jun-ichiro Shirai, Kunihiro Yamasaki, Sho Hirata, Jun-Ichi Ishido, Satoshi |
author_facet | Ogura, Hideki Gohda, Jin Lu, Xiuyuan Yamamoto, Mizuki Takesue, Yoshio Son, Aoi Doi, Sadayuki Matsushita, Kazuyuki Isobe, Fumitaka Fukuda, Yoshihiro Huang, Tai-Ping Ueno, Takamasa Mambo, Naomi Murakami, Hiromoto Kawaguchi, Yasushi Inoue, Jun-ichiro Shirai, Kunihiro Yamasaki, Sho Hirata, Jun-Ichi Ishido, Satoshi |
author_sort | Ogura, Hideki |
collection | PubMed |
description | Although the importance of virus-specific cytotoxic T lymphocytes (CTL) in virus clearance is evident in COVID-19, the characteristics of virus-specific CTLs related to disease severity have not been fully explored. Here we show that the phenotype of virus-specific CTLs against immunoprevalent epitopes in COVID-19 convalescents might differ according to the course of the disease. We establish a cellular screening method that uses artificial antigen presenting cells, expressing HLA-A(*)24:02, the costimulatory molecule 4-1BBL, SARS-CoV-2 structural proteins S, M, and N and non-structural proteins ORF3a and nsp6/ORF1a. The screen implicates SARS-CoV-2 M protein as a frequent target of IFNγ secreting CD8(+) T cells, and identifies M(198–206) as an immunoprevalent epitope in our cohort of HLA-A(*)24:02 positive convalescent COVID-19 patients recovering from mild, moderate and severe disease. Further exploration of M(198–206)-specific CD8(+) T cells with single cell RNA sequencing reveals public TCRs in virus-specific CD8(+) T cells, and shows an exhausted phenotype with less differentiated status in cells from the severe group compared to cells from the moderate group. In summary, this study describes a method to identify T cell epitopes, indicate that dysfunction of virus-specific CTLs might be an important determinant of clinical outcomes. |
format | Online Article Text |
id | pubmed-9758236 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-97582362022-12-18 Dysfunctional Sars-CoV-2-M protein-specific cytotoxic T lymphocytes in patients recovering from severe COVID-19 Ogura, Hideki Gohda, Jin Lu, Xiuyuan Yamamoto, Mizuki Takesue, Yoshio Son, Aoi Doi, Sadayuki Matsushita, Kazuyuki Isobe, Fumitaka Fukuda, Yoshihiro Huang, Tai-Ping Ueno, Takamasa Mambo, Naomi Murakami, Hiromoto Kawaguchi, Yasushi Inoue, Jun-ichiro Shirai, Kunihiro Yamasaki, Sho Hirata, Jun-Ichi Ishido, Satoshi Nat Commun Article Although the importance of virus-specific cytotoxic T lymphocytes (CTL) in virus clearance is evident in COVID-19, the characteristics of virus-specific CTLs related to disease severity have not been fully explored. Here we show that the phenotype of virus-specific CTLs against immunoprevalent epitopes in COVID-19 convalescents might differ according to the course of the disease. We establish a cellular screening method that uses artificial antigen presenting cells, expressing HLA-A(*)24:02, the costimulatory molecule 4-1BBL, SARS-CoV-2 structural proteins S, M, and N and non-structural proteins ORF3a and nsp6/ORF1a. The screen implicates SARS-CoV-2 M protein as a frequent target of IFNγ secreting CD8(+) T cells, and identifies M(198–206) as an immunoprevalent epitope in our cohort of HLA-A(*)24:02 positive convalescent COVID-19 patients recovering from mild, moderate and severe disease. Further exploration of M(198–206)-specific CD8(+) T cells with single cell RNA sequencing reveals public TCRs in virus-specific CD8(+) T cells, and shows an exhausted phenotype with less differentiated status in cells from the severe group compared to cells from the moderate group. In summary, this study describes a method to identify T cell epitopes, indicate that dysfunction of virus-specific CTLs might be an important determinant of clinical outcomes. Nature Publishing Group UK 2022-12-16 /pmc/articles/PMC9758236/ /pubmed/36526616 http://dx.doi.org/10.1038/s41467-022-34655-1 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Ogura, Hideki Gohda, Jin Lu, Xiuyuan Yamamoto, Mizuki Takesue, Yoshio Son, Aoi Doi, Sadayuki Matsushita, Kazuyuki Isobe, Fumitaka Fukuda, Yoshihiro Huang, Tai-Ping Ueno, Takamasa Mambo, Naomi Murakami, Hiromoto Kawaguchi, Yasushi Inoue, Jun-ichiro Shirai, Kunihiro Yamasaki, Sho Hirata, Jun-Ichi Ishido, Satoshi Dysfunctional Sars-CoV-2-M protein-specific cytotoxic T lymphocytes in patients recovering from severe COVID-19 |
title | Dysfunctional Sars-CoV-2-M protein-specific cytotoxic T lymphocytes in patients recovering from severe COVID-19 |
title_full | Dysfunctional Sars-CoV-2-M protein-specific cytotoxic T lymphocytes in patients recovering from severe COVID-19 |
title_fullStr | Dysfunctional Sars-CoV-2-M protein-specific cytotoxic T lymphocytes in patients recovering from severe COVID-19 |
title_full_unstemmed | Dysfunctional Sars-CoV-2-M protein-specific cytotoxic T lymphocytes in patients recovering from severe COVID-19 |
title_short | Dysfunctional Sars-CoV-2-M protein-specific cytotoxic T lymphocytes in patients recovering from severe COVID-19 |
title_sort | dysfunctional sars-cov-2-m protein-specific cytotoxic t lymphocytes in patients recovering from severe covid-19 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9758236/ https://www.ncbi.nlm.nih.gov/pubmed/36526616 http://dx.doi.org/10.1038/s41467-022-34655-1 |
work_keys_str_mv | AT ogurahideki dysfunctionalsarscov2mproteinspecificcytotoxictlymphocytesinpatientsrecoveringfromseverecovid19 AT gohdajin dysfunctionalsarscov2mproteinspecificcytotoxictlymphocytesinpatientsrecoveringfromseverecovid19 AT luxiuyuan dysfunctionalsarscov2mproteinspecificcytotoxictlymphocytesinpatientsrecoveringfromseverecovid19 AT yamamotomizuki dysfunctionalsarscov2mproteinspecificcytotoxictlymphocytesinpatientsrecoveringfromseverecovid19 AT takesueyoshio dysfunctionalsarscov2mproteinspecificcytotoxictlymphocytesinpatientsrecoveringfromseverecovid19 AT sonaoi dysfunctionalsarscov2mproteinspecificcytotoxictlymphocytesinpatientsrecoveringfromseverecovid19 AT doisadayuki dysfunctionalsarscov2mproteinspecificcytotoxictlymphocytesinpatientsrecoveringfromseverecovid19 AT matsushitakazuyuki dysfunctionalsarscov2mproteinspecificcytotoxictlymphocytesinpatientsrecoveringfromseverecovid19 AT isobefumitaka dysfunctionalsarscov2mproteinspecificcytotoxictlymphocytesinpatientsrecoveringfromseverecovid19 AT fukudayoshihiro dysfunctionalsarscov2mproteinspecificcytotoxictlymphocytesinpatientsrecoveringfromseverecovid19 AT huangtaiping dysfunctionalsarscov2mproteinspecificcytotoxictlymphocytesinpatientsrecoveringfromseverecovid19 AT uenotakamasa dysfunctionalsarscov2mproteinspecificcytotoxictlymphocytesinpatientsrecoveringfromseverecovid19 AT mambonaomi dysfunctionalsarscov2mproteinspecificcytotoxictlymphocytesinpatientsrecoveringfromseverecovid19 AT murakamihiromoto dysfunctionalsarscov2mproteinspecificcytotoxictlymphocytesinpatientsrecoveringfromseverecovid19 AT kawaguchiyasushi dysfunctionalsarscov2mproteinspecificcytotoxictlymphocytesinpatientsrecoveringfromseverecovid19 AT inouejunichiro dysfunctionalsarscov2mproteinspecificcytotoxictlymphocytesinpatientsrecoveringfromseverecovid19 AT shiraikunihiro dysfunctionalsarscov2mproteinspecificcytotoxictlymphocytesinpatientsrecoveringfromseverecovid19 AT yamasakisho dysfunctionalsarscov2mproteinspecificcytotoxictlymphocytesinpatientsrecoveringfromseverecovid19 AT hiratajunichi dysfunctionalsarscov2mproteinspecificcytotoxictlymphocytesinpatientsrecoveringfromseverecovid19 AT ishidosatoshi dysfunctionalsarscov2mproteinspecificcytotoxictlymphocytesinpatientsrecoveringfromseverecovid19 |